Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 1% and a transaction volume of 2.6148 million yuan, with an average daily transaction volume of 27.4616 million yuan over the past month [2] - The ETF's scale has increased by 28.6087 million yuan in the past month, ranking first among comparable funds, with a share increase of 12 million units in the last two weeks, also the highest among peers [2] - In terms of capital inflow, the ETF has seen net inflows on 5 out of the last 8 trading days, totaling 14.5271 million yuan [2] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.4, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the past year, suggesting historical low valuations [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.09% of the index, including companies like WuXi Biologics and BeiGene [2] Group 2 - Since the reform of new drug research and development policies in 2015, China's innovative drug industry has developed a strong ecosystem, integrating excellent resources in preclinical and clinical stages, which has gained recognition from multinational corporations (MNCs) [3] - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries, indicating a return of market enthusiasm for the sector [3] - There is a recommendation to focus on international biotech companies, revaluation of innovative pipelines in generic companies, and companies in the CXO industry with significant order and operational improvements [3] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [3]

网易：2025年Q1营收288亿元 同比增7.4% 证监会：2024年对87家拟上市企业开展现场检查或督导 严肃查办5起欺诈发行案件 5月15日，据证监会网站，证监会发布2024年中国证监会执法情况综述。其中提到，2024年，证监会在 发行上市、信息披露、并购重组、退市等重点领域加大执法力度，集中力量精准打击欺诈发行、财务造 假、操纵市场等投资者最关切、最痛恨、最不能容忍的违法违规行为，通过"抓重点、办大案、树导 向"，引导市场主体诚实守信、合规经营，切实维护资本市场秩序和投资者权益。严打欺诈发行，守好 上市"入口关"。欺诈发行从源头上侵蚀市场诚信根基，扭曲资源配置机制，是资本市场"首害"。证监会 秉持"执法全覆盖，申报即担责"原则，全年对87家拟上市企业开展现场检查或督导，严肃查办5起欺诈 发行案件。其中，对高德信、华道生物等拟上市企业报送虚假财务数据行为处以3270万元、1150万元罚 款；对恒大地产欺诈发行债券及信息披露违法处以41.75亿元罚款，对董事长、实际控制人许某印处以 4700万元罚款、终身禁入证券市场，彰显依法从严打击欺诈发行的监管态度和坚定决心。（证监会网 站） 部分银行收紧风控 4月来零 ...

Group 1 - HHLR Fund, L.P. and its affiliates reduced their stake in BeiGene from 6.03% to 4.89%, no longer being a major shareholder [1] - The reduction in stake began in June 2023, with HHLR Fund having previously held 9.02% of shares [1] - The core reason for the reduction is attributed to the fund's typical investment period of around 10 years, with HHLR's investment in BeiGene exceeding 11 years [1] Group 2 - Hillhouse Capital led a $75 million Series A financing round for BeiGene in 2014 and participated in 8 financing rounds [2] - In Q1 2023, BeiGene reported revenue of 8.048 billion yuan, a 50.2% increase from the previous year, and a significantly reduced net loss of 94.5 million yuan [2] - The revenue growth was driven by product sales, particularly from self-developed products, with a notable increase in sales for Zebrutinib and Tislelizumab [2] Group 3 - BeiGene's CEO indicated that the company expects to achieve positive operating profit for the full year of 2025 [3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年5月14日 第 1 頁 共 6 頁 v 1.3.0 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | 說明 | | 人民幣股份 （於上海證券交易所科創板上市，股份代號：688235) | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | ...

Core Viewpoint - Hillhouse Capital, once the second-largest shareholder of BeiGene, is gradually exiting its investment in the company, having reduced its stake below 5% as of May 9, 2023 [1][2]. Shareholder Activity - Hillhouse Capital's HHLR Fund, L.P. and its affiliates sold 16 million shares of BeiGene, reducing their total holdings to 68.55 million shares, which is a decrease in ownership from 6.03% to 4.89% [1]. - Between June 8, 2023, and December 2, 2024, Hillhouse has sold a total of 21.9973 million shares through various trading methods [2]. - In early March 2024, Hillhouse reduced its holdings further by selling 32.24 million shares, bringing its ownership down to 6.66% [2]. Company Performance - BeiGene, a global innovator in cancer treatment, has shown improving financial performance despite Hillhouse's divestment [3]. - For the fiscal year 2024, BeiGene reported revenues of 27.21 billion yuan, a year-on-year increase of 56.2%, while the net loss was 4.98 billion yuan, indicating a reduction in losses for two consecutive years [3]. - In Q1 2025, BeiGene achieved revenues of 8.048 billion yuan, a 50.2% increase year-on-year, with a significantly reduced net loss of 94.5 million yuan compared to a loss of 1.908 billion yuan in the same period last year, marking a 95.05% reduction in losses [3]. - The global sales of BeiGene's flagship product, Baiyueze, reached 5.692 billion yuan in Q1 2025, representing a 63.7% increase and accounting for 70.73% of the company's total revenue [3].

Core Viewpoint - BeiGene has shown significant progress in its financial performance, achieving quarterly profitability for the first time under GAAP in Q1 2025, with a net profit of $1.27 million compared to a net loss of $251 million in the same period last year [1][3]. Financial Performance - In Q1 2025, BeiGene's product revenue reached $1.1 billion, a 47% year-over-year increase, driven primarily by the sales growth of its self-developed products, particularly the BTK inhibitor, Zebrutinib, which contributed over 70% of the revenue [3][4]. - Zebrutinib's global sales in Q1 2025 amounted to $792 million, marking a 62% increase year-over-year, with U.S. sales reaching $563 million, reflecting a significant market share gain [1][3]. - The sales of another key product, PD-1 inhibitor Tislelizumab, reached $171 million, an 18% increase year-over-year, benefiting from rapid expansion in overseas markets [4]. Global Strategy and Market Position - BeiGene is enhancing its global presence by rebranding to BeOne Medicines Ltd. and relocating its registration to Switzerland, aiming to mitigate risks associated with U.S.-China geopolitical tensions [1][5]. - The company has established a new flagship facility in New Jersey, which is expected to bolster its biopharmaceutical production and clinical research capabilities [5]. - BeiGene's sales expenses as a percentage of product revenue decreased from 57% in Q1 2024 to 41% in Q1 2025, indicating improved operational efficiency alongside revenue growth [5]. Future Prospects - The company is optimistic about its BCL2 inhibitor, Sotorasib, which has been submitted for market approval in China and received fast-track designation from the FDA for treating specific blood cancers [6]. - With a current price-to-sales ratio of approximately 5.6 times, BeiGene is positioned for potential shareholder returns as it continues to improve its operating cash flow and profitability [6].

JohnV.Oyler（欧雷强） ，1968年出生，百济神州联合创始人，自2010年起一直担任公司执行董事、董事会 主席兼首席执行官。于1990年获得麻省理工学院的理学学士学位，于1996年获得斯坦福大学的工商管理硕 士学位。欧雷强以管理顾问职务在麦肯锡公司（McKinsey&Company）开始其职业生涯。1997年至1998 年，欧雷强担任GentaIncorporated联席首席执行官，该公司为一家在纳斯达克交易所上市的以肿瘤为重点的 生物制药企业。1998年至2002年，欧雷强创立Telephia,Inc.并担任总裁，该公司于2007年被尼尔森公司 （The Nielsen Company）收购。2002年至2004年，欧雷强担任Galenea Corp的首席执行官，该公司为一家致 力于开发新的中枢神经系统疾病治疗方法的生物制药企业。2005年至2009年，欧雷强担任BioDuro,LLC的总 裁兼首席执行官，该公司为一家药品开发外包公司，后被Pharmaceutical Product Development Inc.收购。 2019年，欧雷强正式入选生物技术产业协会（BIO）董事会及其卫生部门理事 ...

Group 1 - Huate Gas plans to reduce its shareholding by up to 2% through block trading from June 9, 2025, to September 8, 2025, totaling no more than 2.4 million shares [1] - Huazhong Co. reported April sales of 208,200 pigs, with a revenue of 375 million yuan, showing a month-on-month decrease of 4.28% [2] - Haizheng Biomaterials intends to reduce its shareholding by up to 1% starting from June 9, 2025, due to funding needs [3] Group 2 - Lisheng Sports plans to repurchase shares worth between 20 million and 40 million yuan for employee stock ownership plans [5] - Hongjing Technology signed a service contract worth 563 million yuan for a smart computing project, lasting five years [6] - Ugreen Technology aims to participate in the pre-restructuring of Zhongzhi Real Estate, targeting 100% equity acquisition [8] Group 3 - Jingquan Hua plans to reduce its shareholding by up to 1.67% starting from June 6, 2025 [9] - New Times plans to reduce its shareholding by up to 0.3% starting from June 6, 2025 [10] - Baofeng Energy intends to repurchase shares worth between 1 billion and 2 billion yuan, with a maximum price of 22.80 yuan per share [10] Group 4 - Yuanli Co. plans to reduce its shareholding by up to 3% starting from June 6, 2025 [14] - Huakai Yibai intends to reduce its shareholding by up to 3% starting from June 6, 2025 [15] - Guangshengtang's innovative hepatitis B drug GST-HG131 has completed Phase II clinical trials, showing significant efficacy [17] Group 5 - Electric Media plans to invest 115 million yuan in a cultural technology venture capital fund, which has a total expected scale of 2 billion yuan [21] - China Merchants Port reported a total of 17.059 million TEUs in April, a year-on-year increase of 6% [23] - Changguang Huaxin plans to reduce its shareholding by up to 2% starting from June 9, 2025 [25] Group 6 - Huace Film plans to reduce its shareholding by up to 1.11% starting from June 6, 2025, to reduce debt [26] - BeiGene's HHLR Fund reduced its shareholding from 6.03% to 4.89% after selling 16 million shares [27] - Heertai plans to reduce its shareholding by up to 2.05% starting from June 6, 2025 [28] Group 7 - Biyin Lefen's director plans to reduce his shareholding by up to 491,300 shares starting from June 6, 2025, due to personal funding needs [29]

Group 1 - Hillhouse Capital has reduced its stake in BeiGene, selling 16 million shares, bringing its total holdings down to 68.55 million shares, which is 4.89% of the company, no longer making it a major shareholder [1] - The sale occurred on May 9, 2025, at a minimum price of $230.23 per share, resulting in proceeds of approximately $3.68 billion [1] - The stock prices of BeiGene across A-shares, H-shares, and U.S. shares have rebounded this year, with U.S. shares seeing an increase of over 30% [1] Group 2 - Following the reduction of its stake in BeiGene, Hillhouse Capital is set to subscribe to the IPO of Hengrui Medicine [3] - Hengrui Medicine plans to issue 225 million H-shares, with a price range of HKD 41.45 to HKD 44.05 per share, potentially raising up to HKD 13.08 billion [3][4] - The IPO is expected to attract significant interest from international investment institutions, including Hillhouse Capital and others [3] Group 3 - Hengrui Medicine's IPO pricing represents a discount of 19.3% compared to the average A-share price over the past ten days [4] - The company aims for a stable pricing strategy to build investor confidence and ensure successful fundraising, avoiding significant post-listing price volatility [5] - Hengrui Medicine and BeiGene are in a competitive race for the title of "Pharmaceutical King" in the A-share market, with Hengrui currently leading by a market cap of 24 billion yuan as of May 15 [5]

Core Viewpoint - CICC maintains the profit forecast for BeiGene (688235.SH, 06160, ONC.US) for 2025 and 2026, keeping the "outperform" rating, with target prices of 280 CNY, 198 HKD, and 332 USD based on DCF model, indicating upside potential of 15.0%, 41.0%, and 43.1% respectively [1] Group 1 - The company's 1Q25 revenue met expectations, reporting 1.117 billion USD, a 49% year-on-year increase, with product revenue at 1.109 billion USD, up 48%, and a GAAP net profit of 1.27 million USD, exceeding expectations due to revenue growth outpacing operating expenses [2] - Sales of Zanubrutinib reached 792 million USD in 1Q25, a 62% year-on-year increase, accounting for 71.4% of product revenue, with US sales at 563 million USD, up 60%, driven by increased demand, particularly in CLL indications [3] - The company achieved its first quarterly profit turnaround, maintaining guidance for 2025 with expected revenue of 4.9 to 5.3 billion USD, a year-on-year growth of 29% to 39%, and GAAP operating expenses of 4.1 to 4.4 billion USD, projecting a positive GAAP operating profit for 2025 [4] Group 2 - The company has several highlights for 2025-2026, including the approval of BCL2 for R/R CLL treatment, with phase II clinical data expected in 2H25, and plans for a global accelerated filing; ongoing phase II trials for BTK CDAC in r/r CLL with data expected in 2026, and a head-to-head trial with Eli Lilly's Pirto starting in 2025 [5] - In the solid tumor field, preliminary data for CDK4i, CDK2i, and B7H4 ADC is expected in 1H25, with PoC validation for several products planned for 2H25, including collaborations with Amgen on Tarlatamab, which recently met primary clinical endpoints in a phase III trial for 2L SCLC [5]